ClinicaliQ Trial Snapshot
- eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation — Recruiting • Phase III • Respiratory / COPD / Asthma • NCT07177339.
- What is being tested: Depemokimab, a novel therapeutic agent, is being evaluated as an add-on treatment for moderate to severe COPD patients with Type 2 inflammation, with specific focus on the efficacy and safety profile of early intervention initiation.
- Patient eligibility overview: The trial targets individuals with moderate to severe COPD who have evidence of Type 2 inflammatory markers, representing a specific patient subgroup requiring precision-based treatment rather than a broad COPD population.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Depemokimab is being developed as a treatment for individuals with moderate to severe Chronic Obstructive Pulmonary Disorder (COPD). The aim of this study is to assess the efficacy and safety of early initiation of depemokimab as an add-on medicine in participants with moderate to severe COPD with type 2 inflammation.
Eligibility Snapshot
- : * Male or eligible female participants * Eosinophilic phenotype measured using Blood Eosinophil Count (BEC) * Moderate to severe COPD, defined as * A clinically documented history of COPD for at least 1 year * A post-salbutamol Forced expiratory volume in one second (FEV1)/Forced vital capacity (FVC) ratio of less than ()30 percent (%) and = 2 * COPD Assessment Test (CAT) >= 15 * Post-bronchodilator FEV1 < 50% predicted * Chronic bronchitis * Smoking status: Current or former cigarette smokers with a history of cigarette smoking of >=10 pack-years at Screening. * Dual (Inhaled corticosteroid (ICS)+ Long-acting beta2-adrenergic receptor agonist [LABA] or LABA+ Long-acting muscarinic receptor antagonist [LAMA]) or triple (ICS+LABA+LAMA) inhaler therapy as assessed by the investigator for at least 3 months * Body mass index (BMI) >=16 kilograms per square meter (kg/m^2)
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.